Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled salbutamol for premature newborns with respiratory distress syndrome
IRCT20200805048312N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of salbutamol in respiratory distress syndrome (RDS) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Oxygen saturation, Arterial partial pressure of carbon dioxide and 3 more. Started Oct 2020; status: completed.
02
Drugs
salbutamol
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on IRCT20200805048312N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200805048312N1.